AFT Pharmaceuticals United Kingdom latest news

Stay updated with the latest advancements and breakthroughs in the UK pharmaceutical industry.

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More

February 19, 2024

AFT updates operating profit guidance to $23m to $25m

AFT Pharmaceuticals today announces an update to guidance for the financial year to the end of March 2024 (FY24)….

Read More

February 8, 2024

MAXIGESIC<sup>®</sup> SPONSORS THE ONE NZ WARRIORS

AFT Pharmaceuticals announces Maxigesic® is the new Official Pain Relief Partner of the One New Zealand Warriors for the 2024 and 2025 NRL seasons….

Read More

February 7, 2024

Maxigesic IV launched in the United States

AFT Pharmaceuticals announces Maxigesic IV®, the patented intravenous form of its family of pain relief medicines, has today been launched in the US …

Read More

January 19, 2024

AFT further broadens R&D pipeline with new product candidate for Vulva Lichen Sclerosus

AFT Pharmaceuticals announces it has entered into a further partnership with one of its long-standing research and development partners, Belgium’s H…

Read More

January 17, 2024

AFT poised to accelerate momentum in 2024

As the new year commences, AFT Pharmaceuticals is looking forward to building upon the significant progress made during 2023. Last year we moved on fr…

Read More

January 8, 2024

AFT broadens R&D pipeline with new product candidate in Burning Mouth Syndrome

AFT Pharmaceuticals today announces that it has entered into a partnership with one of its research and development partners, Belgium’s Hyloris Phar…

Read More

November 24, 2023

AFT Pharma reports growth and global expansion

FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023…

Read More

October 18, 2023

AFT welcomes US FDA approval for sale of Maxigesic IV<sup>®</sup>

AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, w…

Read More

October 10, 2023

AFT Pharmaceuticals to announce half year interim results

AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended Septemb…

Read More

October 3, 2023

AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director….

Read More

October 3, 2023

Retirement of Jon Lamb

Independent director Jon Lamb today retired from the board following his announcement at the ASM. …

Read More

August 29, 2023

AFT Orphan Pharmaceuticals judgment

AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions L…

Read More

August 10, 2023

Retirement of Jon Lamb Announcement

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the…

Read More

August 10, 2023

AFT Pharmaceuticals 2023 Annual Meeting

Annual Meeting Overview…

Read More

June 30, 2023

Notice of Annual Meeting of Shareholders 2023

<strong>June 30th 2023</strong> Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or t…

Read More

May 23, 2023

Financial Results 2023: AFT declares maiden dividend; record revenue

Financial Results for the 12 Months to 31st of March 2023…

Read More

May 4, 2023

AFT Pharmaceuticals to announce full year results on Monday May 22 2023

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended Mar…

Read More

May 4, 2023

US FDA sets PDUFA date for Maxigesic IV®

AFT Pharmaceuticals today announces the US Food and Drug Administration has set 17 October 2023 as the date by which it expects to respond to AFT’s …

Read More

April 19, 2023

AFT submits Maxigesic IV® packaging data to the US FDA

AFT Pharmaceuticals announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested, as it considers registration…

Read More

April 11, 2023

AFT gains first product registration in China for Crystawash Extend and extends Maxigesic IV licensing

As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 mor…

Read More

March 14, 2023

Maxigesic Rapid® tablets gain US FDA approval

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for t…

Read More

February 2, 2023

AFT to develop antibiotic eye drop

AFT Pharmaceuticals to develop antibiotic eye drop…

Read More

January 9, 2023

2023 New Year letter to investors

AFT Pharmaceuticals releases New Year letter to shareholders….

Read More

November 24, 2022

AFT extends growth investment as sales surge

AFT PHARMACEUTICALS LTD FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2022…

Read More

October 11, 2022

AFT Pharmaceuticals to announce half year interim results on Thursday November 24 2022

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associate…

Read More

July 28, 2022

AFT Completes Pascomer Clinical Study and Takes Back Rights in North America

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associate…

Read More

July 22, 2022

Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals today announces that Dr Doug Wilson will step down from its Board of Directors …

Read More

July 7, 2022

AFT and RooLife launch OTC medicines online in China

AFT Pharmaceuticals and RooLife Group today announce they have launched a range of AFT’s over the counter (OTC) pharmaceuticals through their store …

Read More

April 7, 2022

AFT Sponsors APP Conference 2022 with Crystawash Extend

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021….

Read More

February 24, 2022

AFT Pharmaceuticals partners with Farmaforce

Farmaforce, an award-winning contract sales organisation offering innovative solutions to the Australian pharmaceutical industry, today confirmed its …

Read More

February 15, 2022

AFT launches preservative-free antibacterial eye drop Ocuzo

AFT Pharmaceuticals has opened a new front in its eye drop portfolio, with the introduction of a preservative-free product called Ocuzo for bacterial …

Read More

August 2, 2021

New clinical study shows Novaliq NovaTears<sup>®</sup> +Omega-3 eye drops is significantly effective treatment for dry eye disease.

NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significant…

Read More

July 14, 2021

Maxigesic<sup>®</sup> Oral Liquid gets first regulatory approval

Maxigesic Oral Liquid – a non-opioid analgesic developed for children – achieves first approval in Europe to set up the first global launch and a pa…

Read More

June 9, 2021

AFT at APP 2021

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021….

Read More

May 5, 2021

AFT extends Maxigesic<sup>®</sup> IV license in South America

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extendi…

Read More

April 30, 2021

AFT licenses Maxigesic<sup>®</sup> IV in the US

AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the comme…

Read More

April 2, 2021

About AFT Pharmaceuticals.

With a commitment to innovation, AFT Pharmaceuticals develops, licenses and sells a wide range of products to help improve the health and wellbeing of…

Read More

April 2, 2021

关于AFT制药

AFT制药的承诺是致力于创新,开发、许可和销售范围广泛的产品,以帮助改善人们的健康。…

Read More

March 17, 2021

AFT licenses Pascomer for Europe

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®…

Read More

March 17, 2021

Browse latest news

We develop, license, and sell pharmaceutical products in Australasia and around the world. Check out our latest news….

Read More

March 5, 2021

Maxigesic<sup>®</sup> IV licensed in eight new European markets

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets….

Read More

February 17, 2021

Our range of innovative products

Learn more about our range of products….

Read More

February 17, 2021

创新产品

了解更多产品信息…

Read More

January 13, 2021

AFT confirms demonstration of 24-hour efficacy for Crystawash extend hand sanitiser

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser…

Read More

January 13, 2021

AFT builds North American momentum

Diversified pharmaceutical company appoints new north American-based director and launches Maxigesic® in Canada….

Read More

November 19, 2020

Management financial discussion and analysis for the half year to 30 September 2020

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its por…

Read More

November 19, 2020

Financial results for half year ended 30 September 2020

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its por…

Read More

November 18, 2020

AFT opening European office, signs new partners for maxigesic iv and oral range

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces the establishment of a new subsidiary in Ireland…

Read More

November 9, 2020

AFT welcomes us fda complete response letter

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has received a US Food and Drug Administration (FDA) complete response letter (CRL)….

Read More

November 5, 2020

AFT appoints Anita Baldauf as a director

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a non-executive director….

Read More

November 4, 2020

AFT and Setek sign supply agreement

Agreement covers pharmaceutical-grade medicinal cannabis ingredients for products initially targeted for Australia and New Zealand…

Read More

November 3, 2020

Maxigesic IV® distribution deals signed in UK and Hong Kong

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV® distribution and supply agreements for the UK and Hong Kong, with the compa…

Read More

October 24, 2020

We’re big on 'out-of-the-box' thinking

<strong>We’re big on ‘out-of-the-box’ thinking as innovation truly lies at the heart of our business. Innovation in pharmaceuticals can ta…

Read More

October 23, 2020

Helping to improve lives

Ensuring more people around the globe have access to quality healthcare is an integral part of our ethos. <!–more–> With the support of lo…

Read More

October 23, 2020

Eyes4Everest: providing relief at the top of the world

Eyes4Everest is a charity that delivers eyecare to Himalayan communities. <!–more–> It was founded in 2013 by Sydney optometrist, Shaun Ch…

Read More

October 23, 2020

AusViet: bringing hope and health to disadvantaged people in Australia and Vietnam

AFT Pharmaceuticals was approached by Dr Nguyen Nguyen, a representative of the AusViet Charity Foundation. This charity is a ‘rolling medical commu…

Read More

October 22, 2020

Kiwi Health Flagship Store Launches in China on Tmall Global

ASX-listed RooLife (ASX:RLG) and ASX and NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) have officially launched the New Zealand branded online hea…

Read More

October 14, 2020

AFT Pharmaceuticals to announce half year interim results on Thursday November 19 2020

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Thursday November 19 2020 its half year interim results for the…

Read More

October 11, 2020

Join our team

We’re always looking for talented people, please have a look at the careers we currently have available by visiting our profile on the below Careers…

Read More

October 11, 2020

加入我们的团队

我们一直在寻找有才华的人,请访问下面的职业网站并了解我们目前提供的职业。<!–more–> Our people define us….

Read More

September 13, 2020

Kiwis Thinking About Health

Kiwis Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help New Zealanders live a healthier life. <img src=…

Read More

September 8, 2020

Aussies Thinking About Health

Aussies Thinking About Health is an initiative from AFT Pharmaceuticals that’s designed to help Australians live a healthier life.  <img src=…

Read More

August 24, 2020

Notice of Adjourned Annual Meeting of Shareholders 2020

Notice is hereby given that the adjourned Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be convened and held…

Read More

August 12, 2020

Urgent Adjournment of 2020 Annual Meeting

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) advises that the Annual Meeting of shareholders of AFT scheduled for 10.30am (NZ time) today will …

Read More

July 30, 2020

Maxigesic IV® licensed in six new European nations

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic,…

Read More

July 29, 2020

New Zealand codeine restrictions set for November

AFT Pharmaceuticals (NZX:AFT, ASX:AFT) today welcomes Medsafe's announcement that all codeine and codeine-containing medicines will become prescr…

Read More

July 15, 2020

Notice of Annual Meeting of Shareholders 2020

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (*AFT or the Company*) will be held at the Milford Cruis…

Read More

July 13, 2020

RooLife & AFT launch Online New Zealand Health Store in China

RooLife partners with ASX & NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) to deliver New Zealand branded online health & pharmacy store in…

Read More

July 1, 2020

AFT Pharmaceuticals Share Purchase Plan Oversubscribed

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce that its NZ$2 million share purchase plan (SPP) has closed oversubscribed. …

Read More

June 23, 2020

Nathan Hukill resigns from AFT'S Board

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces Nathan Hukill, president of the company's former major shareholder CRG, has resigned as …

Read More

June 15, 2020

AFT Pharmaceuticals announces opening of Share Purchase Plan

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the opening of its NZ$2 million non-underwritten share purchase plan (SPP)….

Read More

June 11, 2020

AFT Pharmaceuticals announces successful completion of Placement

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the successful completion of its NZ$73.8 million Placement (Placement), com…

Read More

June 10, 2020

AFT Pharmaceuticals announces capital raising to support liquidity and optimise capital structure

AFT Pharmaceuticals (NZX:AFT, ASX:AFP) (AFT, the Company), Atkinson Family Trust (AF Trust) and CRG today announce a capital raising to increase liqui…

Read More

June 5, 2020

Annual Meeting and Closing Date for Director Nominations

AFT Pharmaceuticals Limited (NZX: AFT, ASX: AFP) (AFT) announces that its Annual Meeting of Shareholders is to be held at 10:30am (NZT) on Wednesday 1…

Read More

June 5, 2020

Dispute with PBL Solutions Limited

AFT Pharmaceuticals Limited [NZX: AFT; ASX: AFP] advises that British Virgin Islands incorporated PBL Solutions Limited, the 35% shareholder in AFT&#0…

Read More

June 4, 2020

AFT secures Maxigesic IV® distribution in four Western European countries and reports Australasian market share gains in COVID-19 medicines

AFT Pharmaceuticals (NZX.AFT; ASX.AFP) today announces it has signed an exclusive distribution agreement with Austria's Ever Valinject (Ever) for…

Read More

May 20, 2020

AFT Pharmaceuticals breaks through $100 million revenue and posts record earnings

Highlights…

Read More

May 5, 2020

AFT Pharmaceuticals to announce full year results on Wednesday May 20 2020

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Wednesday May 20 2020 its full year results for the year ended …

Read More

March 23, 2020

AFT finalises refinancing and gives trading update

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has concluded an agreement with the Bank of New Zealand (BNZ) to refinance its current six…

Read More

February 27, 2020

AFT on track to refinance CRG team loan facility

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces that its six-year term loan facility from CRG maturing on 31 March 2020 is on track to be ref…

Read More

February 17, 2020

AFT licenses Maxigesic® IV in 21 new countries across CIS and Central America

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has licensed its Maxigesic® intravenous medicine (Maxigesic® IV) in 21 new countries acr…

Read More

January 28, 2020

AFT notes Maxigesic® sales estimates in new market research

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) notes the publication of new market research that estimates the potential for AFT's patented medicine Ma…

Read More

December 11, 2019

AFT secures Maxigesic® IV distribution in Indonesia

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has signed an exclusive distribution agreement for the registration and commercialisation of Maxigesic IV® i…

Read More

December 6, 2019

AFT welcomes new codeine medicine restrictions

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today welcomes Medsafe's decision to classify all medicines containing codeine as prescription medicines…

Read More

November 27, 2019

Maxigesic to launch in Canada in 2020

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) and Canadian speciality pharmaceutical company Biosyent Pharma Inc., today announce they have concluded an excl…

Read More

November 21, 2019

Financial Results For Half Year Ended 30 September 2019

*AFT earnings rise in line with guidance*…

Read More

November 18, 2019

AFT signs agreements to new markets worth more than US $1 billion

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces it has signed licensing agreements for its Maxigesic pain relief medication in Germany, Pakis…

Read More

November 4, 2019

AFT to book one-off non-cash gain on Pascomer assets

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces it expects to book a one-off non-cash gain of $9.8 million following its previously-announced acquisi…

Read More

October 17, 2019

AFT Pharmaceuticals to announce half year results on Thursday November 21 2019

*AFT Pharmaceuticals to announce half year results on Thursday November 21 2019 *…

Read More

October 8, 2019

AFT and SETEK sign medicinal cannabis MoU

Market and Media Release 8 October 2019…

Read More

July 24, 2019

AFT Pharmaceuticals' achieves first registration of it's patented painkiller Maxigesic IV® in the pivotal Australian market

AFT Pharmaceuticals (‘AFT') today announces it has successfully registered the intravenous form of its successful ‘Maxigesic' pain relief …

Read More

July 22, 2019

Notice of Annual Meeting of Shareholders 2019

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruisin…

Read More

July 22, 2019

AFT Pharma Reaches Licensing Agreement for Pascomer in North America

*AFT Pharma Reaches Licensing Agreement for Pascomer® in North America *…

Read More

July 1, 2019

AFT Pharmaceuticals Grabs #1 Top Seller Spot in Australian Eye Lubricant Market

MAXIGESIC® brand also retains #1 position in paracetamol/ibuprofen analgesic category….

Read More

June 21, 2019

AFT Pharmaceuticals' completes first deal in South America

*AFT signs Maxigesic® Licensing Agreement with Barcelona-based Galenicum Vitae S.L.U for Colombia, Peru and* Chile….

Read More

May 22, 2019

AFT Pharmaceuticals establishes new borrowing facilities

AFT Pharmaceuticals (AFT) today announces it has established a NZ$15 million interim banking facility with the BNZ, enabling the company to commence r…

Read More

May 22, 2019

AFT Pharmaceuticals poised for strong earnings growth

*AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2019*…

Read More

May 6, 2019

Announcement for FY19 Full Year Results

*AFT Pharmaceuticals to announce full year results on Wednesday May 22 2019*…

Read More

April 23, 2019

Clarification

AFT Pharmaceuticals notes that the Sunday Star Times interviewed AFT's founder and CEO Dr Hartley Atkinson for an article which appeared in the S…

Read More

April 12, 2019

AFT Pharmaceuticals' completes new deals for Maxigesic® in Mexico, Switzerland and Cyprus

AFT Pharmaceuticals' completes another 3 deals: Painkiller Maxigesic IV® is now licensed in Mexico together with Maxigesic® tablets in Switzerl…

Read More

January 31, 2019

Atenolol-AFT – NOW AVAILABLE

We are pleased to advise that Atenolol-AFT (atenolol 50 mg/10 mL) oral liquid 300 mL is now back in stock in both Australia and New Zealand….

Read More

September 26, 2018

Atenolol-AFT Update

We currently have a stock shortage of Atenolol-AFT (atenolol 50 mg/10 mL) oral liquid 300 mL in both Australia and New Zealand. The only product curre…

Read More

September 25, 2018

AFT Wins Ventura Supplier of the Year Award 2018

Innovative approach Consistency of stock supply/in stock position Engagement in promotions Over and above mind-set…

Read More

September 10, 2018

Pharmacy Assistant of the Year Award's 2018

AFT Pharmaceuticals is the very proud sponsor of the Pharmacy Assistant of the Year award and is delighted to support the Pharmacy Guild of Australia …

Read More

August 20, 2018

AFT provides support to AusViet Charity

AFT was approached by Dr Nguyen Nguyen, the WA Representative on behalf of the AusViet Charity Foundation (see logo below) This foundation isa non-pro…

Read More

June 1, 2018

Amcal Maxigesic $20,000 Promotion Winners!

Thanks to all those who entered the Maxigesic promotion in TerryWhite Chemmart stores to win a share of $20,000! Congratulations to our 20 winners lis…

Read More

May 31, 2018

TerryWhite Chemmart Maxigesic $20,000 Promotion Winners!

Thanks to all those who entered the Maxigesic promotion in TerryWhite Chemmart stores to win a share of $20,000! Congratulations to our 20 winners lis…

Read More

May 18, 2018

APP 2018 Competition

Thank you for visiting the AFT Pharmaceuticals stand at APP 2018 – it was great to see you!…

Read More

March 19, 2018

Maxigesic Hits No. 1 In Key Australian Painkiller Market

The codeine-free painkiller Maxigesic is now the largest selling Paracetamol-Ibuprofen combination painkiller in Australian pharmacies….

Read More

March 5, 2018

ANZLF 2018

Earlier this week Hartley Atkinson, Managing Director of AFT Pharmaceuticals Ltd was proudly invited to attend The Australian New Zealand Leadership F…

Read More

January 19, 2018

AFT Pharmaceuticals' painkiller Maxigesic now licensed in first North American market, Mexico, taking licensed countries to 125

27-Dec-17…

Read More

January 19, 2018

Prescription-only codeine medicines in New Zealand welcomed

Yesterday the Medicines Classification Committee announced its recommendation that all codeine combination medicines, both analgesics and those used f…

Read More

October 20, 2017

Positive result from large US clinical trial for Maxigesic IV (Intravenous)

AFT Pharmaceuticals (AFT) has today announced the results of the major Phase 3 clinical trial for the intravenous (IV) form of its Maxigesic painkille…

Read More

September 1, 2017

AFT Pharmaceuticals celebrates 20 years of success

Twenty years ago this week, husband and wife Dr Hartley Atkinson and Marree Atkinson, started AFT Pharmaceuticals (AFT) in a room off their home garag…

Read More

May 22, 2017

AFT Pharmaceutical's painkiller Maxigesic now licensed in France, the world's second largest paracetamol and ibuprofen tablet market

AFT Pharmaceuticals (‘AFT') has extended its existing agreements to add a French pharmaceutical company to out-license the product line of its p…

Read More

May 19, 2017

Further European approval puts Maxigesic on path to become leading global paracetamol-ibuprofen painkiller

Chief Executive of AFT Pharmaceuticals, Dr Hartley Atkinson, says that having regulatory approval for these 9 additional countries will open up signif…

Read More

May 12, 2017

Maxigesic on track to access the large United States painkiller market

AFT Pharmaceuticals has been officially notified that the US Food and Drug Administration (FDA) has accepted its application to register its painkille…

Read More

March 22, 2017

AFT Pharmaceuticals In-Licenses NovaTears® in Australia and New Zealand

AFT Pharmaceuticals (AFT) has completed a licensing agreement with Novaliq, a German specialty pharmaceutical company, to distribute NovaTears® in Au…

Read More

January 25, 2017

New Maxigesic agreement for AFT Pharmaceuticals with Leading Nordic Consumer Health Company in Sweden, Norway, Finland, Denmark and Iceland

AFT Pharmaceuticals ('AFT') has licensed the product line of its patented combination painkiller, Maxigesic, in the Nordic region to Weifa A…

Read More

January 9, 2017

New agreement for AFT Pharmaceuticals with Leading European Pharma

AFT Pharmaceuticals (‘AFT') has executed an alliance agreement with privately-owned pharmaceutical company, Angelini, to license the product lin…

Read More

December 20, 2016

TGA decision will boost Maxigesic sales in Australia

*TGA decision will boost Maxigesic sales in Australia*…

Read More

December 7, 2016

AFT hits target to register NasoSURF with the FDA in the United States

AFT Pharmaceuticals (‘AFT) has today announced to investors the completion of a significant milestone in the development of its patented drug deliver…

Read More

May 13, 2016

AFT Pharmaceuticals Strengthens Asian Operations

AFT Pharmaceuticals (AFT) is continuing to build its business operations in South East Asia by moving to the appointment of a Business Manager based i…

Read More

May 13, 2016

Maxigesic Now Licensed in 109 Countries

New agreement for AFT Pharmaceuticals means Maxigesic is now licensed in 109 countries…

Read More

April 19, 2016

Win a chance to be a Maxigesic Millionaire winner named

Congratulations to the winner of our Maxigesic 'win a million' draw Lewis Williams from Priceline Pharmacy, Craigieburn. Lewis has won the c…

Read More

March 23, 2016

Maxigesic to carry Gold Cross logo of the Pharmacy Guild of Australia

Maxigesic to carry Gold Cross logo of the Pharmacy Guild of Australia…

Read More

March 4, 2016

AFT Pharmaceuticals Reaches Agreement for Maxigesic Licensing in 69 Additional Countries

AFT Pharmaceuticals (‘AFT') has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG…

Read More

January 12, 2016

AFT Pharmaceuticals IPO Confirmed

AFT Pharmaceuticals IPO Confirmed and Product Disclosure Statement Lodged…

Read More

January 12, 2016

New medical device to help chronic sinusitis sufferers worldwide

New medical device to help chronic sinusitis sufferers worldwide…

Read More

December 29, 2015

Access to AFT FY16 Interim Report

[assets/Uploads/151229-AFT-FY16-Interim-Report.pdf]Interim Report to 30 September 2015 is now available to view via the following link:…

Read More

December 29, 2015

NZX Interim Announcement

The NZX Interim Announcement to 30 September 2015 is now available to view via the following link. The PDF will download automatically….

Read More

November 19, 2015

Congratulations to the winner of our Maxigesic promotion with Ingenuity Dental

Congratulations Dr. Chris Burton of Noosa Dental Solutions, the lucky winner of our recent Maxigesic trade promotion in conjunction with Ingenuity Den…

Read More

November 9, 2015

Stock Notification: Sandomigran, pizotifen 0.5 mg (as maleate) tablet

*Sandomigran, pizotifen 0.5 mg (as maleate) tablet AUST R69608*…

Read More

November 9, 2015

Further test results available from Woolcock Institute, Sydney

Professor Paul M Young; Head of Respiratory Technology at the Woolcock Institute of Medical Research and Professor in Respiratory Technology at the Sc…

Read More

October 13, 2015

Ferro Pharmacy Promotion Winners Announced

Congratulations to the winners of our Ferro product promotion, which gave Pharmacists nationwide the chance to win $500 drawn weekly over 5 weeks and …

Read More

June 2, 2015

Further US investment in AFT Pharmaceuticals to advance international growth

Specialty Australasian pharmaceutical sales and development company, AFT Pharmaceuticals Ltd (AFT), has finalised a follow-on equity capital raise wit…

Read More

May 22, 2015

New Zealand Herald Profile: AFT Pharmaceuticals

While starting a company with just $50,000, from your garage, may seem a typically Kiwi thing to do, it is much less often that it results in a multi-…

Read More

May 22, 2015

TIN 100: AFT Pharmaceuticals on the rise

AFT Pharmaceuticals has entered the "top 10" to watch list for the first time, with $14.9 million growth in revenues in 2014….

Read More

May 22, 2015

AFT Pharmaceuticals closes important financing to spur global growth

Innovative Australasian pharmaceutical sales and development company, AFT Pharmaceuticals Ltd has finalised an equity and structured debt funding pack…

Read More

May 22, 2015

Views of New Zealand self-medication body at odds with safety concerns of some members

AFT Pharmaceuticals (AFT) has identified a major error with the formulation of over 1300 cold and flu products used around the world….

Read More

May 22, 2015

New York Times: Some cold medicines may have higher than expected levels of a decongestant

Some widely used over-the-counter cold and flu medicines may be exposing patients to unexpectedly high amounts of one ingredient, revealing a lapse in…

Read More

May 22, 2015

Australasian company finds major formulation error with cold and flu products

AFT Pharmaceuticals has identified a major error with the formulation of over 1,300 cold and flu products used around the world….

Read More

May 22, 2015

Maxigesic Pain Relief now available in Australia

Launched this month, MAXIGESIC® is the first analgesic that combines both Paracetamol and Ibuprofen to be registered for use in Australia….

Read More

May 22, 2015

EY Entrepreneur of the Year awards

The founder of AFT Pharmaceuticals, Hartley Atkinson, has been chosen as one of 18 finalists in the EY Entrepreneur of the Year awards….

Read More

May 22, 2015

Femme-Tab ED 20/100 is the first low oestrogen contraceptive pill added to PBS schedule in Australia

The Pharmaceutical Benefits Scheme (Australia) has added a low oestrogen dose combined oral contraceptive (COC) pill for the first time to its schedul…

Read More

May 22, 2015

AFT Pharmaceutical awarded R&D grant by Callaghan Innovation

AFT Pharmaceuticals has today been announced as a recipient of a government Technology Development Grant (TDG) by Callaghan Innovation….

Read More

May 22, 2015

AFT introduces new HYLO-FRESH and HYLO-FORTE

AFT Pharmaceuticals is pleased to announce the launch of new HYLO®-FRESH and HYLO- FORTE® eye drops to the Australian market….

Read More

May 22, 2015

New VitA-Pos Eye Ointment Introduced for night time use

AFT Pharmaceuticals is pleased to announce the launch of the new VitA-POS® eye ointment to the Australian market….

Read More

May 22, 2015

AFT Pharmaceuticals expands operations to South East Asia

The AFT Pharma group is delighted to expand its operations to South East Asia with the establishment of a regional office in Kuala Lumpur….

Read More

May 22, 2015

AFT Pharmaceuticals establishes Orphan Drug Foundation

AFT Pharmaceuticals has commenced an orphan drug company with operations in Auckland, New Zealand; Sydney, Australia and Kuala Lumpur, Malaysia to eff…

Read More

May 22, 2015

AFT picks up Supreme Business award

A Takapuna-based drug company claimed top honours at the 2011 Westpac Auckland North Business Awards at the competition's annual Gala Dinner held…

Read More

May 22, 2015

Phenoxymethylpenicillin-AFT (Penicillin V) now in Australia

In Australia, AFT Pharmaceuticals is delighted to achieve further PBS listings, Phenoxymethylpenicillin-AFT (Penicillin V) Oral Liquid 125mg/5ml &…

Read More

May 22, 2015

PBS listing – Ferro-Tabs

AFT Pharmaceuticals is pleased to announce that from 01 September 2011 it's iron replacement product Ferro-Tabs will be PBS Listed….

Read More

May 22, 2015

Codeine a conundrum for kiwi consumers

A survey has found about a quarter (24 per cent) of New Zealanders who used an over-the-counter painkiller in the past three months took one which con…

Read More

May 22, 2015

New Zealand's world-first combination analgesic

AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibu…

Read More

May 22, 2015

Australiasian drug company challenges industry to go Pseudoephedrine free

Homegrown pharmaceutical company challenges industry to go P-free…

Read More

May 22, 2015

AFT targets $15 billion pain relief market

AFT Pharmaceuticals, a 100 per cent New Zealand owned company, has researched and developed a novel therapy which represents a breakthrough in pain re…

Read More

May 22, 2015

AFT Group Sales Growth continues at +40%

Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 mill…

Read More

May 22, 2015

AFT Pharmaceuticals Expands Australian Presence

AFT Pharmaceuticals has increased its Australian presence with its own dedicated sales team of representatives visiting doctors and pharmacists….

Read More

May 5, 2015

Maxigesic wins best new product award in Australia

This month Maxigesic picked up the the 'Best New Product' award at the 2014 National Convention and Exhibition of the Pharmacy Guild….

Read More

May 5, 2015

Impressive clinical trial results for Maxigesic

AFT Pharmaceuticals has now concluded a pivotal clinical study of 408 patients in the US and NZ. The study will form the basis of AFT's first fil…

Read More

May 5, 2015

Martindale announces AFT as distribution partner for Asia Pacific

Martindale announces AFT as distribution partner for Asia Pacific…

Read More

May 5, 2015

Many Australian pharmacists have concerns about OTC codeine-based analgesics

Some text…

Read More

May 5, 2015

NZ pharmacists concerned about codeine-based analgesics

Some text…

Read More

May 5, 2015

Doctors have alternatives to topical antibitoc treatments

Some text…

Read More

October 28, 2009

Kiwi Co. pops pill into US$20b pain-relief market

New Zealanders will find a home-grown answer to pain relief on the shelves at their local pharmacy this month with the launch of a new drug that repre…

Read More